tiprankstipranks
Trending News
More News >

SpringWorks Therapeutics Completes Merger and Delisting

Story Highlights
SpringWorks Therapeutics Completes Merger and Delisting

Don’t Miss TipRanks’ Half-Year Sale

Springworks Therapeutics ( (SWTX) ) just unveiled an update.

SpringWorks Therapeutics has completed a merger resulting in significant changes to its corporate structure and stockholder rights. As of the effective time of the merger, all shares of the company’s common stock were converted into cash, and stock options and restricted stock units were similarly adjusted. The merger led to the resignation of the company’s board of directors and officers, who were replaced by new appointees. Additionally, SpringWorks has initiated steps to delist from Nasdaq and deregister its common stock, halting trading prior to the merger’s closing date.

The most recent analyst rating on (SWTX) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Springworks Therapeutics stock, see the SWTX Stock Forecast page.

Spark’s Take on SWTX Stock

According to Spark, TipRanks’ AI Analyst, SWTX is a Neutral.

The stock’s score is primarily driven by the positive impact of the merger with Merck, which offers strategic advantages and market expansion opportunities. While technical indicators show bullish trends, the company’s financial performance and valuation reflect current profitability challenges.

To see Spark’s full report on SWTX stock, click here.

More about Springworks Therapeutics

Average Trading Volume: 5,845,527

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.54B

See more data about SWTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1